» Articles » PMID: 31695423

Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2019 Nov 8
PMID 31695423
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Our previous study revealed that nitrogen permease regulator-like-2 (NPRL2), a promising anti-tumor gene, was downregulated at both the blood and tissue levels in CRC patients compared with that in healthy individuals.

Purpose: This study aims to explore the role of NPRL2 in CRC.

Methods: Herein, we constructed NPRL2 overexpression lentivirus vectors and transfected them into HT29 cells. The transfected cells were inoculated subcutaneously into nude mice. Tumor growth, pathology, apoptosis, and the protein expression of caspase-3, caspase-7, Bax, Bcl-2, and phosphorylated protein kinase B (p-Akt) were evaluated. To further explore whether NPRL2 could reduce drug resistance of CRC cells against oxaliplatin (L-OHP) and 5-fluorouracil (5-FU), we constructed a tumor model using HT29 cells. The tumor model was treated with lentiviral particles assembled with vectors encoding NPRL2 and exposed to L-OHP and 5-FU. Tumor growth, pathology, apoptosis, and the protein expression of caspase-3, caspase-7, Bax, Bcl-2, p-Akt, P-glycoprotein (P-gp), and multidrug resistance protein 1 (MRP1) were evaluated.

Results: The results indicated that in the in vivo CRC xenograft model, NPRL2 reduced the tumor volume and weight and enhanced apoptosis. Our results also confirmed that NPRL2 enhanced the sensitivity of CRC cells to L-OHP and 5-FU. Our studies further demonstrated that NPRL2 exerted anti-tumor and anti-drug resistance effects through the caspase-3, caspase-7, Bax, Bcl-2, Akt, P-gp, and MRP1 pathways.

Conclusion: Our present work demonstrated that NPRL2 exhibited anti-tumor effects and enhanced the sensitivities of CRC cells to L-OHP and 5-FU through the P-gp and MRP1 pathways.

Citing Articles

gene therapy induces effective antitumor immunity in mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.

Meraz I, Majidi M, Song R, Meng F, Gao L, Wang Q Elife. 2025; 13.

PMID: 39932765 PMC: 11813225. DOI: 10.7554/eLife.98258.


NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression.

Wang Y, Tsai M, Chen Y, Hsieh P, Hung C, Lin H Hepatol Commun. 2022; 6(12):3563-3577.

PMID: 36321403 PMC: 9701468. DOI: 10.1002/hep4.2019.


Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma.

Pi Y, Zhan Y, Song J, Jin X, Chen J J Gastrointest Oncol. 2022; 13(4):1589-1604.

PMID: 36092347 PMC: 9459220. DOI: 10.21037/jgo-22-115.


SEA and GATOR 10 Years Later.

Loissell-Baltazar Y, Dokudovskaya S Cells. 2021; 10(10).

PMID: 34685669 PMC: 8534245. DOI: 10.3390/cells10102689.


Improving anti-tumor outcomes for colorectal cancer therapy through thermosensitive gel loading harmine.

Li Z, Chen L, He C, Han Y, Han M, Zhang Y Am J Transl Res. 2020; 12(5):1658-1671.

PMID: 32509167 PMC: 7270021.

References
1.
Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

2.
Ma Y, Silveri L, LaCava J, Dokudovskaya S . Tumor suppressor NPRL2 induces ROS production and DNA damage response. Sci Rep. 2017; 7(1):15311. PMC: 5681675. DOI: 10.1038/s41598-017-15497-0. View

3.
Brody H . Colorectal cancer. Nature. 2015; 521(7551):S1. DOI: 10.1038/521S1a. View

4.
Liu A, Liu D, Du Y, Pei F, Yang G, Liu B . Relationship between tumor and peripheral blood NPRL2 mRNA levels in patients with colorectal adenoma and colorectal cancer. Cancer Biol Ther. 2014; 15(5):489-95. PMC: 4026070. DOI: 10.4161/cbt.28016. View

5.
Liu M, Liu A, Du Y, Pei F, Wang X, Chen J . Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells. Mol Med Rep. 2015; 12(1):1189-96. DOI: 10.3892/mmr.2015.3495. View